Expression of cancer-testis antigen CT7 (MAGE-C1) in breast cancer: An immunohistochemical study with emphasis on prognostic utility

Pathology and Oncology Research

Volumn 13, Issue 2, 2007, Pages 91-96

  Krüger, Stefan ^a,b   Ola, Vladislava ^a   Feller, Alfred C ^a   Fischer, Dorothea ^a   Friedrich, Michael ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Breast cancer; Cancer testis antigen; CT7; Immunohistochemistry; MAGE C1; Prognosis

Indexed keywords

CANCER TESTIS ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; PROGESTERONE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION;

EID: 34547635804     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02893483     Document Type: Article

References (28)

1. Van den Eynde BJ, van der Bruggen P: T cell defined tumor antigens. Curr Opin Immunol 9: 684-693, 1997.
2. Takahashi K, Shichijo S, Noguchi M, et al: Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res 55: 3478-3482, 1995.
3. Scanlan MJ, Gure AO, Jungbluth AA, et al: Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188: 22-32, 2002.
4. Suri A: Cancer testis antigens - their importance in immunotherapy and in the early detection of cancer. Expert Opin Ther 6: 379-389, 2006.
5. Marchand M, van Baren N, Weiynants P, et al: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 18: 219-230, 1999.
6. Banchereau J, Palucka AK, Dhodapkar M, et al: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dentritic cell vaccine. Cancer Res 61: 6451-6458, 2001.
7. Coulie PG, Karanikas V, Colau D, et al: A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 98: 10290-10295, 2001.
8. Bettinotti MP, Panelli MC, Ruppe E, et al: Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178. Int J Cancer 105: 210-216, 2003.
9. Marchand M, Punt CJ, Aamdal S, et al: Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 39: 70-77, 2003.
10. Kruit WH, van Ojik HH, Brichard VG, et al: Phase 1/2 study of subcutaneous and intradermal immunization with recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 117: 596-604, 2005.
11. van Baren N, Bonnet MC, Dreno B, et al: Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 23: 9008-9021, 2005.
12. Sadanaga N, Nagashima H, Mashino K, et al: Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 7: 2277-2284, 2001.
13. Russo V, Traversari C, Verrecchia A, et al: Expression of the MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy. Int J Cancer 64: 216-221, 1995.
14. Jungbluth AA, Chen YT, Busam KJ, et al: CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues. Int J Cancer 99: 839-845, 2002.
15. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
16. Chitale DA, Jungbluth AA, Marshall DS, et al: Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray. Mod Pathol 18: 119-126, 2005.
17. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930-942, 1998.
18. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467, 1998.
19. Danish Breast Cancer Cooperative Group: Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group BBCG 82b and c randomized studies. J Clin Oncol: 24: 2268-2275, 2006.
20. Yamanaka K, Miyake H, Hara I, et al: Expression of MAGE genes in renal cell carcinoma. Int J Mol Med 2: 57-60, 1998.
21. Patard JJ, Brasseur F, Gil-Diez S, et al: Expression of MAGE genes in transitional cell carcinomas of the urinary bladder. Int J Cancer 64: 60-64, 1995.
22. Toh Y, Yamana H, Shichijo S, et al: Expression of MAGE-1 gene by esophageal carcinomas. Jpn J Cancer Res 86: 714-717, 1995.
23. Nagao T, Higashitsuji H, Nonoguchi K, et al: MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J Biol Chem 278: 10668-10674, 2003.
24. Peikert T, Specks U, Farver C, et al: Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis. Cancer Res 66: 4693-4700, 2006.
25. Monte M, Simonatto M, Peche LY, et al: MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 103: 11160-11165, 2006.
26. Riker A, Cormier J, Panelli M, et al: Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126: 112-120, 1999.
27. El-Shami K, Tirosh B, Bar-Haim E, et al: MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur J Immunol 29: 3295-3301, 1999.
28. Markiewicz MA, Fallarino F, Ashikari A, et al: Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int Immunol 13: 625-632, 2001.